

Special Issue

Varicella Zoster Virus: Recent Advances, Risks and Prevention in Infants and Adults in Particular (during Immunomodulating Therapy)

Message from the Guest Editor

Varicella zoster virus (VZV) is a worldwide pathogen and may result in many complications. As it remains dormant in the nervous system, VZV, which is responsible for herpes zoster in sometimes severe forms, may reactivate later in life. A decrease in the effectiveness of the cellular immune responses due to age, disease, or treatments may explain the increased risk of herpes zoster in populations exhibiting these risk factors. A live attenuated VZV vaccine is available and was approved by FDA in 1995. Vaccination is recommended in some countries like the US and Australia. A live attenuated herpes zoster vaccine has been proven effective and safe in immunocompetent patients. The effectiveness and safety of the herpes zoster vaccine in patients with immunodeficiencies has also been recently demonstrated. This Special Issue will focus on recent research related to the epidemiology of VZV in infants and adults, and recent advances in prevention (vaccination), treatment, and management of varicella and herpes zoster in immunocompromised patients.

Guest Editor

Prof. Dr. Françoise Lunel-Fabiani
CHU Angers, France

Deadline for manuscript submissions

closed (30 November 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/55082

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).